Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial

Published:2018-03 Issue:3 Volume:19 Page:405-415
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Atkins Michael B,Plimack Elizabeth R,Puzanov Igor,Fishman Mayer N,McDermott David F,Cho Daniel C,Vaishampayan Ulka,George Saby,Olencki Thomas E,Tarazi Jamal C,Rosbrook Brad,Fernandez Kathrine C,Lechuga Mariajose,Choueiri Toni K

Funder

Genentech

Exelixis

Merck

Horizon Pharma

Novartis

Eisai

Roche

AstraZeneca

Prometheus

Pfizer

Astellas Pharma US

Bristol-Myers Squibb

Eli Lilly and Company

Bayer Corporation

Publisher

Elsevier BV

Subject

Oncology

Reference32 articles.

1. Modes of resistance to anti-angiogenic therapy;Bergers;Nat Rev Cancer,2008

2. Molecular mechanisms of resistance to tumour anti-angiogenic strategies;Grepin;J Oncol,2010

3. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired;Ahmadzadeh;Blood,2009

4. Inhibitory B7-family molecules in the tumour microenvironment;Zou;Nat Rev Immunol,2008

5. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up;Thompson;Cancer Res,2006

Cited by 311 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overcoming Cancer Resistance: Strategies and Modalities for Effective Treatment;Biomedicines;2024-08-08

2. Small molecule inhibitors as adjuvants in cancer immunotherapy: enhancing efficacy and overcoming resistance;Frontiers in Immunology;2024-08-05

3. A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302);BMC Cancer;2024-07-25

4. Promoting reactive oxygen species accumulation to overcome tyrosine kinase inhibitor resistance in cancer;Cancer Cell International;2024-07-09

5. Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis;eClinicalMedicine;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3